NLA Resources
PCSK9 Inhibitors
9 Resources
Knowledge Center
The National Lipid Association is your destination for the science of lipid medicine. Now, everything we know is in one place.
PCSK9 Inhibitors
5 Available Resources
US Food and Drug Administration Approves LIB Therapeutics’ LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
CINCINNATI, Ohio – December 15, 2025 – LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on…
Amgen Makes Repatha® Available Through AmgenNow, A Direct-to-patient Program in the US
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolucumab).…
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened…
Novartis Receives FDA Approval for Label Update On Use of Leqvio (Inclisiran)
Novartis received FDA approval for a label update that will allow for use of Leqvio ® (inclisiran) in certain patients…
S1E1: Clinical Pearls on Provider Methods for Obtaining Prior Authorizations for PCSK9i
Join Dr. Alan Brown and Dr. Kim Birtcher as they discuss the complexities of prior authorizations and what methods providers…
Enhancing the Value of PCSK9 Monoclonal Antibodies (MAb)
Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit: A consensus statement from the National Lipid Association
Acquisition costs and cost-effectiveness have limited access and recommendations to use proprotein convertase subtilisin/kexin type 9 (PCSK9)–inhibiting monoclonal antibodies (mAbs).
Inclisiran: Where Will It Fit?
Inclisiran (Leqvio; Novartis) is now the first small interfering RNA (siRNA) therapy to be approved by the FDA to reduce…
Cutting Costs without Compromising Care: Affordable Approaches to Lipid-Lowering Medications
Introduction Atherosclerotic Cardiovascular disease (ASCVD) is the leading cause of death worldwide, and uncontrolled lipids are a major modifiable risk factor…
Join the NLA
Become A Member
When you become a member of the NLA, you become part of a collegial multidisciplinary group of leaders dedicated to improving lipid and cardiometabolic health.
